Point-of-care pharmacogenetic testing specialist Genedrive announced on Friday that clinical performance data for its ...

Shares in Genedrive were up 4.5% at 2.38 pence each in London after the results were released on Friday morning.

The best explored example of this phenomenon is the CYP2C19 polymorphism. In this table the most frequent alleles are presented that are important for the clinical practice [11,16]. Data on rare ...

A large segment of the CYP2C19 rapid metabolizer subgroup is nonresponder to the PPI treatment, only partial symptom relief in GERD, more frequent unsuccessful eradication therapy and lower ...

Nostra Terra Oil & Gas Co PLC, up 18% at 0.025p, 12-month range 0.021p-0.1725p. City broker Peel Hunt LLP has a 10.08% stake in the Texas, US-focused oil producer as of Monday, up from none reported ...

(LON:GDR – Get Free Report) shares fell 8% during trading on Tuesday . The stock traded as low as GBX 2.25 ($0.03) and last traded at GBX 2.30 ($0.03). 1,411,990 shares were traded during mid-day ...

2023年12月16日，科华生物正式发布公告，宣布其控股子公司西安天隆科技有限公司的两项产品获得国家药监局颁发的医疗器械注册证。这两项产品分别为实时荧光定量PCR仪和人类CYP2C19基因多态性检测试剂盒 ...

在实际应用中，科华生物的PCR产品已在多家医院和检测中心得到广泛应用。许多用户反馈表示，设备的检测速度和准确率均超过了他们的预期，设备在多个重要项目中的表现尤其突出。例如，在新冠病毒筛查时，实时荧光定量PCR仪能够在保持高准确度的同时，缩短检测时间， ...

科华生物公告，实时荧光定量PCR仪、人类CYP2C19基因多态性检测试剂盒（荧光PCR法）获得医疗器械注册证。 平台声明：该文观点仅代表作者本人，搜狐号系信息发布平台，搜狐仅提供信息存储空间服务。

智通财经APP讯，科华生物(002022.SZ)发布公告，近日，公司控股子公司西安天隆科技有限公司收到国家药品监督管理局颁发的医疗器械注册证。涉及产品：“实时荧光定量PCR仪”、“人类CYP2C19基因多态性检测试剂盒(荧光PCR法)”。以上新产品医 ...

每经AI快讯， 科华生物 公告，控股子公司西安天隆科技有限公司收到国家药品监督管理局颁发的医疗器械注册证。产品名称分别为实时荧光定量PCR仪、人类CYP2C19基因多态性检测试剂盒 （荧光PCR法）。

格隆汇12月16日丨科华生物(002022.SZ)公布，近日，公司控股子公司西安天隆科技有限公司两项产品收到国家药品监督管理局颁发的医疗器械注册证。产品名称分别为实时荧光定量PCR仪及人类CYP2C19基因多态性检测试剂盒(荧光PCR法)。